Caribou Biosciences CRBU 深 沪
等待开盘 09-25 09:30:00 美东时间
1.26
-0.030
-2.33%
华盛通- 最 高1.29
- 今 开1.29
- 成交量 58.86万股
- 最 低 1.25
- 昨 收 1.29
- 总市值 1.35亿
- 52周最高 3.535
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 1.25
- 委 比 24.06%
- 总股本 1.07亿
- 历史最高 32.645
- 量 比 1.06
- 振 幅 3.10%
- 历史最低 0.66
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Abivax Presents Business Updates and First Half 2026 Financial Results
Abivax reported business updates and first half 2026 financial results, including the appointment of Chris Rabbat as Chief Medical Officer and Tim Kelly as Chief Technical Officer. The company has a cash runway into Q4 2029, following the completion of a public offering and royalty certificate buy-back. R&D expenses increased due to new indications and clinical trial advancements, while G&A and sales/marketing expenses also rose to support future...
09-21 20:05
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5
B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $6 to $5.
08-15 02:25
Caribou Biosciences Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $1.499M Miss $2.279M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 25 percent. This is a 31.43 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $1.499 millio...
08-14 04:24
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Caribou Biosciences reported Q2 2026 financial results and business updates, highlighting clinical data for vispa-cel and CB-011. Vispa-cel demonstrated durable responses in 2L LBCL patients, with an 82% ORR and 67% CR rate. CB-011 showed deep responses in high-risk MM patients, achieving a 92% ORR and 83% CR rate. The company plans pivotal trials for vispa-cel and expects to report initial CB-011 dose expansion data in H2 2026. Financially, the ...
08-13 20:05
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
Olema Pharmaceuticals, Inc. ("Olema Oncology") announced the appointment of Jason O’Byrne, MBA, as Chief Financial Officer. O’Byrne brings over 20 years of finance and global operations leadership in biotech and pharma. He previously served as CFO at Vir Biotechnology and Caribou Biosciences, leading financial and capital markets initiatives, including IPOs and acquisitions. Olema Oncology is advancing therapies for breast cancer, with palazestra...
08-13 11:00
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Raises Price Target to $11
HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and raises the price target from $9 to $11.
05-11 19:32
Caribou Biosciences Q1 EPS $(0.26) Beats $(0.31) Estimate, Sales $2.397M Beat $2.241M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 39.53 percent increase over losses of $(0.43) per share
05-08 04:46
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
